Advanced glycation end-products and cathepsin cysteine protease in type 2 diabetic patients

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 7-8, 2013, Pages 364-370

  Grzebyk, Ewa ^a   Knapik Kordecka, Maria ^a   Piwowar, Agnieszka ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Advanced glycation end products; Cathepsin B; Cysteine proteases; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CATHEPSIN B;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME ACTIVITY; FEMALE; FLUORESCENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; MOLECULAR WEIGHT; PROCEDURES; SPECTROFLUOROMETRY;

ADULT; CATHEPSIN B; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; SPECTROMETRY, FLUORESCENCE;

EID: 84885116919     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1821     Document Type: Article

References (30)

1. Méndez JD, Xie J, Aguilar-Hernández M, Méndez- Valenzuela V. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem. 2010; 341: 33-41.
2. Moheimani F, Kim CH, Rahmanto AS, et al. Inhibition of lysosomal function in macrophages incubated with elevated glucose concentrations: a potential contributory factor in diabetes-associated atherosclerosis. Atherosclerosis. 2012; 223: 144-151.
3. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol. 2008; 45: 1-16.
4. Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008; 4: 1143-1152.
5. Thomas MC, Forbes J, MacIsaac R, et al. Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more? Ann N Y Acad Sci. 2005; 1043: 644-654.
6. Gerdemann A, Lemke HD, Nothdurft A et al. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. Clin Nephrol. 2000; 54: 276-283.
7. Zeng J, Dunlop RA, Rodgers KJ, Davies MJ. Evidence for inactivation of cysteine proteases by reactive carbonyls via glycation of active site thiols. Biochem J. 2006; 398: 197-206.
8. Grimm S, Horlacher M, Catalgol B, et al. Cathepsin D and L reduce the toxicity of advanced glycation end products. Free Radic Biol Med. 2012; 52: 1011-1023.
9. Cheng XW, Huang Z, Kuzuya M, et al. Cysteine protese cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension. 2011; 58: 978-986.
10. Lutgens S, Cleutjens K, Daemen M, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007; 21: 3029-3041.
11. Reisner J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. 2010; 120: 3421-3431.
12. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001; 17: 4629-4633.
13. Gupta A, Tripathi AK, Tripathi RL, et al. Advanced glycosylated end products-mediated activation of polymorphonuclear neutrophils in diabetes mellitus and associated oxidative stress. Indian J Biochem Biophys. 2007; 44: 373-378.
14. Nagai R, Fujiwara Y, Mera K, et al. Investigation of pathways of advanced glycation end-products accumulation in macrophages. Mol Nutr Food Res. 2007; 51: 462-467.
15. Grimm S, Ernst L, Grötzinger N, et al. Cathepsin D is one of the major enzymes involved in intracellular degradation of AGE-modified proteins. Free Radic Res. 2010; 44: 1013-1026.
16. Jobs E, Risérus U, Ingelsson E, et al. Serum cathepsin S is associated with decreased insulin sensitivity and the development of type 2 diabetes in a community-based cohort of elderly men. Diabetes Care. 2013; 36: 163-165.
17. Zeman K, Tchórzewski H, Majewska E, et al. [Simple and rapid method of simultaneous isolation from peripheral blood highly cleaned lymphocytes and neutrophils]. Immunol Pol. 1988; 23: 217-224. Polish.
18. Barret AJ. Fluorimetric assays for cathepsin B and cathepsin h with methylcoumarylamide substrates. Biochem J. 1980; 187: 909-912.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193: 265-275.
20. Münch G, Keis R, Wessels A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem. 1997; 9: 669-677.
21. Wróbel K, Wróbel K, Garay-Sevilla ME, et al. Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem. 1997; 9: 1563-1569.
22. Morgan PE, Dean RT, Davies MJ. Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products. Arch Biochem Biophys. 2002; 403: 259-269.
23. Kalousová M, Skrha J, Zima T. Advanced glycation end products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res. 2002; 51: 597-604.
24. Sharp P, Rainbow S, Mukherjee S. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet Med. 2003; 20: 575-579.
25. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab. 2006; 9: 233-245.
26. Nishimura F, Naruishi K, Yamada H, et al. High glucose suppresses cathepsin activity in periodontal-ligament-derived fibroblastic cells. J Dent Res. 2000; 79: 1614-1617.
27. Piwowar A, Zurawska-Płaksej E, Knapik-Kordecka M, et al. Cell surface-bound of cathepsin B and leukocyte elastase expression on polymorphonuclear leukocytes in type 2 diabetes. Acta Biochim Pol. 2007; 54: 14-15.
28. Warwas M, Piwowar A, Knapik Kordecka M. Cathepsin B activity and other proteases and glycosydases in plasma patients with insulindependent daibetes mellitus. Diagn Lab. 1999; 35: 413-419.
29. Piwowar A, Knapik-Kordecka M, Warwas M. Level of cathepsin B in polymorphonuclear neutrophils in diabetes mellitus type 2. Diagn Lab. 2001; 37: 303-310.
30. Piwowar A, Knapik-Kordecka M, Warwas M. Influence of oral hypoglycemic drugs on Cathepsin B activit in polymorphonuclear leukocyte. Farm Pol. 2008; 64: 942-949.